Eye-Sparing Treatment for Diffuse Invasive Conjunctival Melanoma

The management of patients with diffuse invasive conjunctival melanoma focuses on local tumor control and screening for metastasis. Despite the lack of consensus on the benefit of sentinel lymph node biopsy for these neoplasms, the information obtained by histopathology is useful for tumor staging a...

Full description

Saved in:
Bibliographic Details
Published in:Ocular oncology and pathology 2018-06, Vol.4 (4), p.261-266
Main Authors: Chaves, Leandro J., Huth, Bradley, Augsburger, James J., Correa, Zelia M.
Format: Article
Language:English
Subjects:
Novel Insights from Clinical Practice
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c424t-a40f644cb63e24253937ee401feda9bf96052a3ebd0dfe323a972426174292423
cites cdi_FETCH-LOGICAL-c424t-a40f644cb63e24253937ee401feda9bf96052a3ebd0dfe323a972426174292423
container_end_page 266
container_issue 4
container_start_page 261
container_title Ocular oncology and pathology
container_volume 4
creator Chaves, Leandro J.
Huth, Bradley
Augsburger, James J.
Correa, Zelia M.
description The management of patients with diffuse invasive conjunctival melanoma focuses on local tumor control and screening for metastasis. Despite the lack of consensus on the benefit of sentinel lymph node biopsy for these neoplasms, the information obtained by histopathology is useful for tumor staging and treatment planning. Due to the lack of evidence of survival improvement, orbital exenteration is being performed with diminishing frequency. We describe a patient with diffuse invasive conjunctival melanoma and lymph node involvement treated by tumor debulking, brachytherapy (custom unshielded radioactive device), and adjuvant ipilimumab who has had a favorable outcome without emergence of local tumor relapse or distant metastasis during 16 months of follow up.
doi_str_mv 10.1159/000485978
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_30643772</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2179339289</sourcerecordid><originalsourceid>FETCH-LOGICAL-c424t-a40f644cb63e24253937ee401feda9bf96052a3ebd0dfe323a972426174292423</originalsourceid><addsrcrecordid>eNpt0E1LwzAYB_AgipO5g3eRghc9VPPWtLmIMqcOJhOc55C1T2ZnX2bSDvbtjWwWBU95ID_-zwtCJwRfERLJa4wxTyIZJ3voiFIpQi6ieL-rE9JDA-eWnhEueRSJQ9RjWHAWx_QI3Y42EL6utM2rRTCzoJsSqiYwtQ3uc2NaB8G4WmuXryEY1tWyrdImX-sieIZCV3Wpj9GB0YWDwe7to7eH0Wz4FE6mj-Ph3SRMOeVNqDk2gvN0LhhQTiMmWQzAMTGQaTk3UuCIagbzDGcGGGVaxt4JEnMqfcH66Gabu2rnJWSpn9LqQq1sXmq7UbXO1d-fKn9Xi3qtBKMUJ9wHXOwCbP3ZgmtUmbsUCr8G1K1TlMSSMUkT6enllqa2ds6C6doQrL6Prrqje3v2e65O_pzYg_Mt-NB2AbYD0-nLNkKtMuPV6b9q1-ULXSaQ_w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2179339289</pqid></control><display><type>article</type><title>Eye-Sparing Treatment for Diffuse Invasive Conjunctival Melanoma</title><source>PubMed Central</source><creator>Chaves, Leandro J. ; Huth, Bradley ; Augsburger, James J. ; Correa, Zelia M.</creator><creatorcontrib>Chaves, Leandro J. ; Huth, Bradley ; Augsburger, James J. ; Correa, Zelia M.</creatorcontrib><description>The management of patients with diffuse invasive conjunctival melanoma focuses on local tumor control and screening for metastasis. Despite the lack of consensus on the benefit of sentinel lymph node biopsy for these neoplasms, the information obtained by histopathology is useful for tumor staging and treatment planning. Due to the lack of evidence of survival improvement, orbital exenteration is being performed with diminishing frequency. We describe a patient with diffuse invasive conjunctival melanoma and lymph node involvement treated by tumor debulking, brachytherapy (custom unshielded radioactive device), and adjuvant ipilimumab who has had a favorable outcome without emergence of local tumor relapse or distant metastasis during 16 months of follow up.</description><identifier>ISSN: 2296-4681</identifier><identifier>EISSN: 2296-4657</identifier><identifier>DOI: 10.1159/000485978</identifier><identifier>PMID: 30643772</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Novel Insights from Clinical Practice</subject><ispartof>Ocular oncology and pathology, 2018-06, Vol.4 (4), p.261-266</ispartof><rights>2018 S. Karger AG, Basel</rights><rights>Copyright © 2018 by S. Karger AG, Basel 2018</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c424t-a40f644cb63e24253937ee401feda9bf96052a3ebd0dfe323a972426174292423</citedby><cites>FETCH-LOGICAL-c424t-a40f644cb63e24253937ee401feda9bf96052a3ebd0dfe323a972426174292423</cites><orcidid>0000-0003-2946-3757</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322084/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322084/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30643772$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chaves, Leandro J.</creatorcontrib><creatorcontrib>Huth, Bradley</creatorcontrib><creatorcontrib>Augsburger, James J.</creatorcontrib><creatorcontrib>Correa, Zelia M.</creatorcontrib><title>Eye-Sparing Treatment for Diffuse Invasive Conjunctival Melanoma</title><title>Ocular oncology and pathology</title><addtitle>Ocul Oncol Pathol</addtitle><description>The management of patients with diffuse invasive conjunctival melanoma focuses on local tumor control and screening for metastasis. Despite the lack of consensus on the benefit of sentinel lymph node biopsy for these neoplasms, the information obtained by histopathology is useful for tumor staging and treatment planning. Due to the lack of evidence of survival improvement, orbital exenteration is being performed with diminishing frequency. We describe a patient with diffuse invasive conjunctival melanoma and lymph node involvement treated by tumor debulking, brachytherapy (custom unshielded radioactive device), and adjuvant ipilimumab who has had a favorable outcome without emergence of local tumor relapse or distant metastasis during 16 months of follow up.</description><subject>Novel Insights from Clinical Practice</subject><issn>2296-4681</issn><issn>2296-4657</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNpt0E1LwzAYB_AgipO5g3eRghc9VPPWtLmIMqcOJhOc55C1T2ZnX2bSDvbtjWwWBU95ID_-zwtCJwRfERLJa4wxTyIZJ3voiFIpQi6ieL-rE9JDA-eWnhEueRSJQ9RjWHAWx_QI3Y42EL6utM2rRTCzoJsSqiYwtQ3uc2NaB8G4WmuXryEY1tWyrdImX-sieIZCV3Wpj9GB0YWDwe7to7eH0Wz4FE6mj-Ph3SRMOeVNqDk2gvN0LhhQTiMmWQzAMTGQaTk3UuCIagbzDGcGGGVaxt4JEnMqfcH66Gabu2rnJWSpn9LqQq1sXmq7UbXO1d-fKn9Xi3qtBKMUJ9wHXOwCbP3ZgmtUmbsUCr8G1K1TlMSSMUkT6enllqa2ds6C6doQrL6Prrqje3v2e65O_pzYg_Mt-NB2AbYD0-nLNkKtMuPV6b9q1-ULXSaQ_w</recordid><startdate>20180601</startdate><enddate>20180601</enddate><creator>Chaves, Leandro J.</creator><creator>Huth, Bradley</creator><creator>Augsburger, James J.</creator><creator>Correa, Zelia M.</creator><general>S. Karger AG</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2946-3757</orcidid></search><sort><creationdate>20180601</creationdate><title>Eye-Sparing Treatment for Diffuse Invasive Conjunctival Melanoma</title><author>Chaves, Leandro J. ; Huth, Bradley ; Augsburger, James J. ; Correa, Zelia M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c424t-a40f644cb63e24253937ee401feda9bf96052a3ebd0dfe323a972426174292423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Novel Insights from Clinical Practice</topic><toplevel>online_resources</toplevel><creatorcontrib>Chaves, Leandro J.</creatorcontrib><creatorcontrib>Huth, Bradley</creatorcontrib><creatorcontrib>Augsburger, James J.</creatorcontrib><creatorcontrib>Correa, Zelia M.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Ocular oncology and pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chaves, Leandro J.</au><au>Huth, Bradley</au><au>Augsburger, James J.</au><au>Correa, Zelia M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Eye-Sparing Treatment for Diffuse Invasive Conjunctival Melanoma</atitle><jtitle>Ocular oncology and pathology</jtitle><addtitle>Ocul Oncol Pathol</addtitle><date>2018-06-01</date><risdate>2018</risdate><volume>4</volume><issue>4</issue><spage>261</spage><epage>266</epage><pages>261-266</pages><issn>2296-4681</issn><eissn>2296-4657</eissn><abstract>The management of patients with diffuse invasive conjunctival melanoma focuses on local tumor control and screening for metastasis. Despite the lack of consensus on the benefit of sentinel lymph node biopsy for these neoplasms, the information obtained by histopathology is useful for tumor staging and treatment planning. Due to the lack of evidence of survival improvement, orbital exenteration is being performed with diminishing frequency. We describe a patient with diffuse invasive conjunctival melanoma and lymph node involvement treated by tumor debulking, brachytherapy (custom unshielded radioactive device), and adjuvant ipilimumab who has had a favorable outcome without emergence of local tumor relapse or distant metastasis during 16 months of follow up.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>30643772</pmid><doi>10.1159/000485978</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-2946-3757</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2296-4681
ispartof Ocular oncology and pathology, 2018-06, Vol.4 (4), p.261-266
issn 2296-4681
2296-4657
language eng
recordid cdi_pubmed_primary_30643772
source PubMed Central
subjects Novel Insights from Clinical Practice
title Eye-Sparing Treatment for Diffuse Invasive Conjunctival Melanoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T05%3A35%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Eye-Sparing%20Treatment%20for%20Diffuse%20Invasive%20Conjunctival%20Melanoma&rft.jtitle=Ocular%20oncology%20and%20pathology&rft.au=Chaves,%20Leandro%C2%A0J.&rft.date=2018-06-01&rft.volume=4&rft.issue=4&rft.spage=261&rft.epage=266&rft.pages=261-266&rft.issn=2296-4681&rft.eissn=2296-4657&rft_id=info:doi/10.1159/000485978&rft_dat=%3Cproquest_pubme%3E2179339289%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c424t-a40f644cb63e24253937ee401feda9bf96052a3ebd0dfe323a972426174292423%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2179339289&rft_id=info:pmid/30643772&rfr_iscdi=true